[Which hormone therapy should be used in advanced breast carcinoma in males?]

Dtsch Med Wochenschr. 1988 Sep 2;113(35):1358-61. doi: 10.1055/s-2008-1067820.
[Article in German]

Abstract

A 76-year-old man with advanced carcinoma of the breast who had not been orchiectomized underwent sequential hormonal treatment. The tumour progressed during monotherapy with dexamethasone. Objective regression of the tumour followed sequential administration of tamoxifen (twice) and the two aromatase inhibitors, aminoglutethimide and testololactone. In addition, his condition remained stable on two progestogens in high doses, medroxyprogesterone acetate and megestrol acetate.

Publication types

  • Case Reports

MeSH terms

  • Adenocarcinoma / drug therapy*
  • Adenocarcinoma / surgery
  • Aged
  • Aminoglutethimide / therapeutic use*
  • Axilla
  • Breast Neoplasms / drug therapy*
  • Breast Neoplasms / surgery
  • Dexamethasone / therapeutic use
  • Drug Evaluation
  • Humans
  • Lymphatic Metastasis
  • Male
  • Medroxyprogesterone / analogs & derivatives
  • Medroxyprogesterone / therapeutic use
  • Medroxyprogesterone Acetate
  • Megestrol / analogs & derivatives
  • Megestrol / therapeutic use
  • Megestrol Acetate
  • Tamoxifen / therapeutic use*
  • Testolactone / analogs & derivatives*
  • Testolactone / therapeutic use
  • Testosterone Congeners / therapeutic use*

Substances

  • Testosterone Congeners
  • Tamoxifen
  • Aminoglutethimide
  • testololactone
  • Testolactone
  • Dexamethasone
  • Medroxyprogesterone Acetate
  • Megestrol
  • Medroxyprogesterone
  • Megestrol Acetate